Histone Deacetylase Inhibition Destabilizes the Multi-Potent State of Uncommitted Adipose-Derived Mesenchymal Stromal Cells

Bookmarking Target Genes in Mitosis: A Shared Epigenetic Trait of Phenotypic Transcription Factors and Oncogenes?

(2014) Sayyed K. Zaidi et al.   CANCER RESEARCH

Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo

(2013) Song Xu et al.   ACTA PHARMACOLOGICA SINICA

Histone Deacetylase Inhibition Promotes Osteoblast Maturation by Altering the Histone H4 Epigenome and Reduces Akt Phosphorylation

(2013) Amel Dudakovic et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Histone Deacetylase 3 Suppression Increases PH Domain and Leucine-rich Repeat Phosphatase (Phlpp)1 Expression in Chondrocytes to Suppress Akt Signaling and Matrix Secretion

(2013) Elizabeth W. Bradley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer

(2013) Emily K Mader et al.   Journal of Translational Medicine

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions

(2013) Daehwan Kim et al.   GENOME BIOLOGY

Histone Deacetylase Inhibitor Trichostatin A Promotes the Osteogenic Differentiation of Rat Adipose-Derived Stem Cells by Altering the Epigenetic Modifications on Runx2 Promoter in a BMP Signaling-Dependent Manner

(2012) Xiaoqing Hu et al.   STEM CELLS AND DEVELOPMENT

Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts

(2011) Meghan E. McGee-Lawrence et al.   BONE

HDAC inhibitors in HIV

(2011) Fiona Wightman et al.   IMMUNOLOGY AND CELL BIOLOGY

PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma

(2011) J R Molina et al.   ONCOGENE

Platelet Lysate Consisting of a Natural Repair Proteome Supports Human Mesenchymal Stem Cell Proliferation and Chromosomal Stability

(2010) Ruben Crespo-Diaz et al.   CELL TRANSPLANTATION

Adverse effects of valproate on bone: Defining a model to investigate the pathophysiology

(2010) Susan M. Senn et al.   EPILEPSIA

Histone deacetylases in skeletal development and bone mass maintenance

(2010) Meghan E. McGee-Lawrence et al.   GENE

Redundant Control of Adipogenesis by Histone Deacetylases 1 and 2

(2010) Michael Haberland et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss

(2010) J. Pratap et al.   MOLECULAR CANCER THERAPEUTICS

WNT5A Regulates Chondrocyte Differentiation through Differential Use of the CaN/NFAT and IKK/NF-κB Pathways

(2010) Elizabeth W. Bradley et al.   MOLECULAR ENDOCRINOLOGY

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS

Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells

(2009) S. Lee et al.   CELL PROLIFERATION

Mesenchymal Stem Cells for Bone Repair and Metabolic Bone Diseases

(2009) Anita H. Undale et al.   MAYO CLINIC PROCEEDINGS

Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis

(2009) Darren M Hutt et al.   Nature Chemical Biology

PDGF, TGF- , and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages

(2008) F. Ng et al.   BLOOD

Histone Deacetylase Inhibitors Promote Apoptosis and Senescence in Human Mesenchymal Stem Cells

(2008) Giovanni Di Bernardo et al.   STEM CELLS AND DEVELOPMENT